Kodiak Sciences Inc (KOD)
KOD moved a median of +0.09% 30 minutes after news, and -0.13% by the close. How KOD actually reacts to news — the realized, point-in-time move the market made, measured across 138 labeled events over the last three years with zero look-ahead.
KOD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.15% | 52% | 137 |
| 30-min | +0.09% | 51% | 138 |
| 60-min | +0.34% | 52% | 138 |
| to close | -0.13% | 48% | 136 |
| Middle 50% of KOD reactions | -1.66% to +2.21% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 138 |
Half of all Kodiak Sciences Inc news events land between -1.66% and +2.21% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KOD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 22 | +0.52% | 64% | -1.95% |
| Coverage initiations | 12 | -1.56% | 33% | +1.22% |
| Rating reiterations | 32 | -0.66% | 47% | +0.59% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how KOD ranks against every other measured name →
That’s how KOD usually reacts — get an email when it moves on news →Email me when KOD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KOD's baseline. Nothing else.
Recent KOD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026 | Press release | PR Newswire | -1.51% | -0.72% | |
| Form 8-K Kodiak Sciences Inc. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | +18.37% | +46.66% | |
| Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interv | Press release | PR Newswire | +18.37% | +46.66% | |
| Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration | Press release | PR Newswire | +18.37% | +46.66% | |
| Form 10-Q Kodiak Sciences Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.67% | +10.56% | |
| Form 8-K Kodiak Sciences Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +3.67% | +10.56% | |
| Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results | Press release | PR Newswire | +3.67% | +10.56% | |
| Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 | Press release | PR Newswire | +0.38% | +3.98% | |
| Form 8-K Kodiak Sciences Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +1.62% | -8.68% | |
| Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference | Press release | PR Newswire | -0.74% | +0.19% | |
| Form 10-Q Kodiak Sciences Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.84% | -2.47% | |
| Form 8-K Kodiak Sciences Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +3.84% | -2.47% | |
| Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | Press release | PR Newswire | +3.84% | -2.47% | |
| Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences | Press release | PR Newswire | +0.76% | +1.71% | |
| Form ARS Kodiak Sciences Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.34% | +0.09% | |
| Form DEF 14A Kodiak Sciences Inc. For: Jun 02 | SEC filing · Form DEF | SEC EDGAR | +0.34% | +0.09% | |
| Form DEFA14A Kodiak Sciences Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.34% | +0.09% | |
| Form 10-K Kodiak Sciences Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.25% | +7.62% | |
| Form 8-K Kodiak Sciences Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +7.62% | |
| Form S-8 Kodiak Sciences Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.25% | +7.62% | |
| Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results | Press release | PR Newswire | -0.25% | +7.62% | |
| Form 8-K Kodiak Sciences Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -6.02% | -11.65% | |
| Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham | Press release | PR Newswire | -2.17% | +12.10% | |
| Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 | Press release | PR Newswire | +0.35% | -6.91% | |
| Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.04% | -0.49% | |
| Form 8-K Kodiak Sciences Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | +0.00% | |
| Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares | Press release | PR Newswire | +2.35% | +0.00% | |
| Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock | Press release | PR Newswire | +3.19% | +2.31% | |
| Kodiak Sciences Announces Proposed Public Offering of Common Stock | Press release | PR Newswire | +4.01% | +11.25% | |
| Kodiak Sciences to Present at Upcoming Investor Conferences | Press release | PR Newswire | -1.15% | — | |
| Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (=90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) | Press release | PR Newswire | -1.52% | -1.49% | |
| New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) | Press release | PR Newswire | +1.04% | -2.71% | |
| Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI) | Press release | PR Newswire | +0.79% | -2.60% | |
| Harbour BioMed Reports 2025 Interim Results | Press release | PR Newswire | +0.18% | +1.30% | |
| Kodiak Sciences to Present at American Chemical Society Fall 2025 | Press release | PR Newswire | — | — | |
| Form 10-Q Kodiak Sciences Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.32% | +7.72% | |
| Form 8-K Kodiak Sciences Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +7.72% | |
| Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results | Press release | PR Newswire | +0.32% | +7.72% | |
| Kodiak Sciences to Host Investor R&D Day on July 16, 2025 | Press release | PR Newswire | -0.22% | +0.67% | |
| Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society | Press release | PR Newswire | -0.67% | +1.61% | |
| Form 8-K Kodiak Sciences Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | -0.25% | |
| Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference | Press release | PR Newswire | -4.51% | -4.22% | |
| Form 10-Q Kodiak Sciences Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.93% | -12.83% | |
| Form 8-K Kodiak Sciences Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -3.93% | -12.83% | |
| Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results | Press release | PR Newswire | -3.93% | -12.83% | |
| Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases | Press release | PR Newswire | +3.46% | +6.20% | |
| Form ARS Kodiak Sciences Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +5.06% | +1.01% | |
| Form DEF 14A Kodiak Sciences Inc. For: Jun 02 | SEC filing · Form DEF | SEC EDGAR | +5.06% | +1.01% | |
| Form DEFA14A Kodiak Sciences Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +5.06% | +1.01% | |
| Form 10-K Kodiak Sciences Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.65% | -2.02% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KOD section they belong to.
Where else KOD is measured.
KOD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BELEAVE INC ORD (BLEVF) | 138 | -0.70% | 33% |
| BIOMERIEUX 69 MARCY NEW (BMXMF) | 138 | 0.00% | 23% |
| Fonar Corporation (FONR) | 137 | 0.00% | 34% |
| Biomerica, Inc. (BMRA) | 135 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kodiak Sciences Inc's median reaction calculated?
Every labeled KOD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 138 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of KOD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KOD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.